Lisinopril Stada

Lisinopril Stada

lisinopril

Manufacturer:

Stada

Distributor:

DCH Auriga
Concise Prescribing Info
Contents
Lisinopril
Indications/Uses
Arterial HTN; as an adjunct to non-K sparing diuretics &/or digitalis in cardiac insufficiency; as an adjunct to nitrates in acute MI (AMI) in patients w/ a stable cardiocirculatory situation.
Dosage/Direction for Use
Arterial HTN Initially 5 mg once daily in the morning. Titrate dose at intervals of ≥3 wk until optimal BP attained. Maintenance: 10-20 mg once daily. Max: 40 mg once daily in the morning. Cardiac insufficiency 2.5 mg once daily in the morning. Titrate dose in steps of 2.5 mg at intervals of at least 2-4 wk. Max: 35 mg daily. AMI in haemodynamically stable patients Initially 5 mg, followed by 5 mg after 24 hr & 10 mg after 48 hr. Continue for 6 wk at a min maintenance dose of 5 mg once daily. Renal impairment (CrCl 30-70 mL/min) & elderly (>65 yr) Initially 2.5 mg once daily in the morning. Maintenance: 5-10 mg daily. Max: 20 mg daily.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity to lisinopril or other ACE inhibitors or one of the other ingredients.. Renal artery stenosis (bilateral or unilateral in a solitary kidney); history of hereditary or idiopathic angioneurotic oedema due to ACE inhibitors; post-renal transplantation; severe renal impairment (CrCl <30 mL/min); hemodialysis; aortic or mitral valve stenosis; hypertrophic cardiomyopathy; haemodynamic instability post acute MI; systolic BP ≤100 mmHg; cardiogenic shock. Concomitant use w/ poly(acrylonitrite, Na-2 methylallysulfonate)-high-flux-membrane (eg AN 69); aliskiren-containing products in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m2). May cause injury or death to developing foetus when used during the 2nd & 3rd trimesters of pregnancy; discontinue immediately when pregnancy is detected. Lactation.
Special Precautions
Hypovolemia, hyponatraemia; concomitant high dose diuretic or vasodilator therapy; preexisting hypotension; instable cardiac insufficiency; severe or renovascular HTN; renal impairment; acute MI; angina pectoris; cerebrovascular angiopathy; malignant HTN; severe myocardial insufficiency; conditions predisposing to hyperkalaemia; vascular or connective tissue disorders. Concurrent immunosuppressive therapy. Primary hyperaldosteronism. Proteinuria, LDL lipid apheresis/desensitisation, tissue swelling/angioneurotic oedema, aortic stenosis/hypertrophic myocardiopathy, neutropenia/agranulocytosis, operation/anaesth. Concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren. May impair ability to drive or operate machinery. Childn. Elderly ≥70 yr.
Adverse Reactions
Dizziness, weakness, impaired vision, syncope; tachycardia, palpitations, arrhythmia, chest pain, angina pectoris, heart attack, transitory ischemic attack, stroke; cardiogenic shock; 2nd- & 3rd-degree AV block, severe hypotension, impaired renal function; resp: dry cough, sore throat, hoarseness & bronchitis, laboured respiration, sinusitis, rhinitis, bronchospasm/asthma, pulmonary infiltration, stomatitis, glossitis, dry mouth, angioneurotic oedema, alveolitis; GI/liver: nausea, abdominal pain, indigestion, vomiting, diarrhea, constipation, lack of appetite, jaundice, liver insufficiency, hepatitis, liver failure, pancreatitis & ileus; skin & blood vessel disorders: rash, urticaria, itching (pruritus), angioneurotic oedema, pemphigus, erythema multiforme, exfoliative dermatitis, Stevens-Johnson's syndrome, toxic epidermal necrolysis, psoriasis, photosensitivity, flush, perspiration, hair & nail loss (onycholysis), vascular cramps worsening in Raynaud syndrome; headache & tiredness; decrease Hb conc, haematocrit, leucocytes or thrombocytes.
Drug Interactions
Enhanced antihypertensive effect w/ diuretics & other antihypertensives. Increase serum K conc w/ K-sparing diuretics eg, spironolactone, triamterene or amiloride, K prep or K-containing salt supplements. Lowers hypotensive & heart failure relieving effect w/ NaCl. Lower BP-reducing effect w/ NSAIDs (eg aspirin, indomethacin), sympathomimetics. Reduced elimination of lithium. Enhance the effect of alcohol. Alcohol increases the BP-reducing effect of ACE inhibitors. Increase BP fall w/ anaesth, narcotics, hypnotics (sleeping pills). Concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia & decreased renal function (including acute renal failure). Increased risk for leucopenia w/ allopurinol, medication that suppresses the defense reaction (cytostatics, immunosuppressives, systemic corticoids) & procainamide. Enhance blood sugar-reducing effect of oral antidiabetics & insulin. Reduce bioavailability w/ antacids.
ATC Classification
C09AA03 - lisinopril ; Belongs to the class of ACE inhibitors. Used in the treatment of cardiovascular disease.
Presentation/Packing
Form
Lisinopril Stada tab 10 mg
Packing/Price
100's
Form
Lisinopril Stada tab 20 mg
Packing/Price
100's
Form
Lisinopril Stada tab 5 mg
Packing/Price
100's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in